ID   BHP 17-10
AC   CVCL_6281
SY   BHP17-10; BHP-17
DR   BioSample; SAMN03151828
DR   cancercelllines; CVCL_6281
DR   Cosmic; 1005451
DR   Cosmic; 1094769
DR   Wikidata; Q54796494
RX   PubMed=8675585;
RX   PubMed=9253346;
RX   PubMed=18713817;
RX   PubMed=20143388;
WW   https://iclac.org/wp-content/uploads/Cross-Contaminations_v12_distribution.xlsx
CC   Problematic cell line: Contaminated. Shown to be a M14 derivative (PubMed=18713817; PubMed=20143388). Originally thought to originate from a thyroid gland papillary carcinoma.
CC   Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00181.
CC   Population: Caucasian.
CC   Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; c.150+2T>C (IVS1+2T>C); ClinVar=VCV000406712; Zygosity=Heterozygous; Note=Splice donor mutation (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; c.455insCdel26; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly266Glu (c.797G>A); ClinVar=VCV000161516; Zygosity=Heterozygous (from parent cell line).
CC   Derived from site: Metastatic; Right buttock, hypodermis; UBERON=UBERON_0013691+UBERON_0002072.
ST   Source(s): PubMed=18713817
ST   Amelogenin: X
ST   D13S317: 12
ST   D18S51: 13,17
ST   D21S11: 30
ST   D3S1358: 14,16
ST   D5S818: 11,12
ST   D7S820: 8,10
ST   D8S1179: 13
ST   FGA: 21
ST   vWA: 16,18
DI   NCIt; C3802; Amelanotic melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_1395 ! M14
SX   Male
AG   33Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 25
//
RX   PubMed=8675585; DOI=10.1210/jcem.81.7.8675585;
RA   Ohta K., Pang X.-P., Berg L., Hershman J.M.;
RT   "Antitumor actions of cytokines on new human papillary thyroid
RT   carcinoma cell lines.";
RL   J. Clin. Endocrinol. Metab. 81:2607-2612(1996).
//
RX   PubMed=9253346; DOI=10.1210/jcem.82.8.4136;
RA   Ohta K., Pang X.-P., Berg L., Hershman J.M.;
RT   "Growth inhibition of new human thyroid carcinoma cell lines by
RT   activation of adenylate cyclase through the beta-adrenergic
RT   receptor.";
RL   J. Clin. Endocrinol. Metab. 82:2633-2638(1997).
//
RX   PubMed=18713817; DOI=10.1210/jc.2008-1102;
RA   Schweppe R.E., Klopper J.P., Korch C.T., Pugazhenthi U., Benezra M.,
RA   Knauf J.A., Fagin J.A., Marlow L.A., Copland J.A. III, Smallridge R.C.,
RA   Haugen B.R.;
RT   "Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer
RT   cell lines reveals cross-contamination resulting in cell line
RT   redundancy and misidentification.";
RL   J. Clin. Endocrinol. Metab. 93:4331-4341(2008).
//
RX   PubMed=20143388; DOI=10.1002/ijc.25242;
RA   Capes-Davis A., Theodosopoulos G., Atkin I., Drexler H.G., Kohara A.,
RA   MacLeod R.A.F., Masters J.R.W., Nakamura Y., Reid Y.A., Reddel R.R.,
RA   Freshney R.I.;
RT   "Check your cultures! A list of cross-contaminated or misidentified
RT   cell lines.";
RL   Int. J. Cancer 127:1-8(2010).
//